Generation Bio Co expected to post a loss of 28 cents a share - Earnings Preview

Generation Bio

06/11/2024 04:59

* Generation Bio Co  GBIO.OQ   GBIO.O  is expected to show a
fall
in quarterly revenue when it reports  results on November 7
(estimated) for the period ending September 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 12.3% decrease in revenue to $1.882 million from $2.15 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Generation Bio Co is for
a
loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Generation
Bio Co
is $7.50​, above​ its last closing price of $2.19. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.29       -0.28      -0.31     Missed  -11.3
 Mar. 31 2024  -0.40       -0.41      -1.12     Missed  -174.4
 Jan. 1 0001   -0.44       -0.45      -0.53     Missed  -18.2​
 Jan. 1 0001   -0.50       -0.50      -0.43     Beat    14.9
 ​​Jan.        -0.50       -0.50      -0.47     Beat    5.4
 1 0001                                                 
 Mar. 31 2023  -0.45       -0.46      -0.53     Missed  -14.2​
 Dec. 31 2022  -0.58       -0.58      -0.55     Beat    5
 Sep. 30 2022  -0.66       -0.67      -0.53     Beat    21.1
 This summary was machine generated November 6 at 04:58 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)